Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

E. A. Sausville^*, S. G. Arbuck, R. Messmann, D. Headlee, K. S. Bauer, R. M. Lush, A. Murgo, W. D. Figg, T. Lahuse, S. Jaken, X. X. Jing, M. Roberge, E. Fuse, T. Kuwabara, A. M. Senderowicz

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review